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acid based cream in the prevention of radiation induced skin 
toxicity (RIST). 
 
Material and Methods: Patients undergoing breast irradiation 
after conservative surgery for breast cancer were considered 
for the study. The patients were randomly assigned to use T-
lysyal (repalysyal, a thymine-lysine-hyaluronic acid based 
cream) vs. patients using a moisturizing cream. The patients 
were stratified for age, breast size, and phototype. Radiation 
therapy was delivered with 3D conformal radiation therapy, 
with 20 fraction of 2.25 Gy (concomitant boost dose 2.5 Gy) 
on the residual breast for a total dose of 45 Gy in 4 weeks (50 
Gy boost dose to the tumoral bed). The appearance of any 
grade of skin toxicity was the endpoint of our study. RIST was 
assessed weekly from the beginning of treatment and graded 
according to the RTOG acute skin toxicity scale. 
 
Results: Fifty two consecutive patients undergoing radiation 
therapy after breast conserving surgery for breast cancer 
were randomized to have the skin treated with 2 daily 
application of Repalysyal or a simple moisturizing cream. 
Median age of the patients was 54. At the end of treatment 
(4 weeks) 15/26 patients in the Repalysyal group vs. 26/26 
patients in the control group had any grade of skin toxicity 
(p=0.0001). Moreover, among patients that developed skin 
toxicity, 3/15 vs. 18/26 developed G2 toxicity in Repalysial 
and control group, respectively (0.0036). 
 
Conclusion: Repalysyal ameliorates the acute skin toxicity 
profile of patients undergoing radiation therapy after 
conservative surgery for breast cancer. 
 
EP-1188  
The protective role of lipofilling in women subjected to 
radiotherapy. 
N. Costantino1, V.M. Margheriti
1University Of Catanzaro "Magna Graecia", Oncology 
Radiotherapy, Catanzaro, Italy 
1, M. Santoro2, E. Mazzei2, 
M.A. Molinaro2, R. Mole'2, A. Destito2, D. Pingitore2, C. 
Bianco1 
2Hospital Of Catanzaro "Pugliese-Ciaccio", Oncology 
Radiotherapy, Catanzaro, Italy 
 
Purpose or Objective: Many authors suggest, when the 
patients is suitable, the complete reconstruction of the 
breast which has undergone radiation by autologous tissue, 
discouraging prosthetic placing because of the high level of 
post-radiotherapic complications observed. The aim of this 
study is the assessment of radiation-induced outcomes in 
women with breast cancer who have been subjected to 
radiotherapy after reconstruction. 
 
Material and Methods: Between January 2011 and March 
2013 we chose 17 patients, median age of 45 years; 15 of 
these had undergone a radical mastectomy and 2 a 
quadrantectomy. During the mastectomy 7 patients were 
given an immediate prothesis, 9 underwent reconstruction by 
lipofilling by way of classical breast expander and following 
prothesis , 1 quadrantectomy and breast remodelling by 
lipofilling. All the patients received adjuvant chemiotherapy 
and/or hormonotherapy, conformational radiotherapy on the 
thoracic wall or residue breast(total dose of 50 Gy) and local 
prophilactic therapy so as to minimize the radiation-induced 
adverse effects. All patients have gone thruogh a clinical-
instrumental follow-up over an median time of 12 months and 
an assessment of cutaneous toxicity according to the SOMA-
LENT scale. 
 
Results: It was observed in 2 of the cases capsular 
contracture of the prothesis of high grade which needed 
further replacing and apperance of cutaneous ulcers (grade 
2) in 1 patient ;in the remaining cases of prosthetic 
reconstruction erythema and edema were found (grade2). A 
tolerable erythema was observed in the patients with 
expander and simultaneous lipofilling without late fibrosis. 
No complications were found in the patients with rimodelling 
by lipofilling post quadrantectomy, with conservation of the 
shape and simmetry of the breast. 
Conclusion: The grafting of the autologous fat, high in 
stamina cells, represents an alternative technique in breast 
reconstruction with complete functional recovery of the 
tissue , so improving the the surrounding tissue and therefore 
the capacity to heal in the irradiated tissues. The use of 
lipofilling is becoming an ever increasing importance as a 
coadjuvant in the breast reconstruction and avoids 
radiotherapy-induced complications. This gives notable 
psychophysical benefits and improves the quality of life in 
the patients. 
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Purpose or Objective: Whole breast irradiation (WBI) is the 
gold standard after breast conserving surgery (BCS), followed 
by an additional boost when negative prognostic factors are 
present. WBI can be administered with hypofractionated 
schedules, on the basis of the relatively low α/β ratio for 
breast cancer (BC). The aim of our study was to investigate 
the effects of an additional hypofractionated boost (HB) in 
terms of acute and short-term late skin and subcutaneous 
tissue toxicity. 
 
Material and Methods: Between March 2014 and April 2015 
156 women, median age 62 years (range 34-88) with early BC 
(pT1-pT2, N0-N1) underwent hypofractionated RT (single 
dose of 2.65 Gy to 42.4 Gy in 16 fractions over 3 weeks) ± HB 
(single dose 2.65 Gy to 10.6 Gy in 4 fractions). The study 
enrolled 71 patients (pts) without HB (45.5%) and 85 with HB 
(54.5%). The additional HB was delivered if risk factors such 
as young age, positive nodes, negative hormonal receptors, 
high Ki67 or HER2/neu overexpression were present. 
According to the risk of relapse chemotherapy (CT) and/or 
Hormonal Therapy (HT) and/or Trastuzumab were 
administered. For the analysis of the acute and late toxicity 
CTCAE 4.03 scale was used. Pts had physical examination at 
5th, 10th, 16th and 20th day of RT and then 1 and 6 months 
after the end of treatment. Statistical analysis was carried 
out by the Chi-square test and the Mann–Whitney's U-test was 
used to compare continuous variables. 
 
Results: HB group characteristics were: younger age (median 
56 vs 67), longer time gap between surgery and RT (median 
time 20 weeks vs 16), more advance stage (43.6 % stage II vs 
14.1%), CT (37 pts vs 2), HT (71 pts vs 48). Hypofractionated 
RT was well tolerated with or without HB and no G3 overall 
toxicity was documented. HB did not contribute to major skin 
toxicity; at the end of the treatment only 14 cases had G2 
dermatitis vs 5 which did not receive HB (p = 0.073).One 
month after RT HB and CT significantly impacted upon edema 
occurrence: 15.5% HB group vs 1.5% no HB (p = 0.008) and 
18.4 % CT group vs 6.2% no CT (p = 0.016). Furthermore, CT 
emerged as a risk factor for hyperpigmentation 6 months 
after RT: 37.0% vs 10.4% (p = 0.003). Attached Table 
summarizes the toxicity time-related events. 
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Conclusion: Administration of an additional HB is feasible, 
safe and well tolerated in terms of acute and short-term late 
skin and subcutaneous toxicity even though it seems to have 
a role in the edema occurrence. Although G2 dermatitis 
occurred in 16.47% of pts receiving HB vs 7.04% not receiving 
it, the difference was not significant, probably due to few 
observed events. Long term follow up data and a larger 
sample size are needed to confirm these data, assess late 
toxicity and clinical outcomes. 
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Purpose or Objective: The aim of this study was to compare 
the volumes obtained with surgical clips during breast 
conserving surgery of breast cancer patients with volume 
determined using FDG positive tumor volumes outlined in 
pre-operative PET-CT imaging and find out the deviations 
that arise. 
 
Material and Methods: For initial diagnostic PET-CT 
requested by the surgeon, the patients were positioned on 
the breast board with the arm on the ipsilateral side up. 
Those without metastatic tumors and applicable for breast 
conserving surgery went under operation in compliance with 
oncoplastic surgery principles. 4 clips were placed at the 
tumor lodge. For 15 of the patients, before continuing with 
further therapy, the tumor volume outlined with the surgical 
clips and that contoured using the area with FDG affinity 
viewed on the PET-CT were determined. Results were 
statistically analyzed with SPSS software. 
 
Results: This study determined that methods used in 
oncoplastic surgery (such as flap shifting) resulted in 
displacements of the tumors from their original locations. For 
statistics we apply paired t test to the results that we have 
from these different techniques and found the values 
respectively for x,y,z as 0.929, 0.119, 0.991. Even the p 
value that we found is higher than 0.05 and not seems to be 
significant when we evaluate the center of mass deviation 
that we measure with these two techniques makes us to have 
an impact in overall results. 
 
Conclusion: Determination of boost volume using pre-op 
tumor volume is not trustable in cases where tumor volume is 
not marked using clips during oncoplastic surgery of breast 
cancer and may result in geographical misses. 
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Purpose or Objective: To investigate the association 
between the molecular sub-types and the pattern of distant 
metastasis in carcinoma breast. 
 
Material and Methods: 400 patients of locally advanced 
breast carcinoma, without any distant metastasis, both 
clinically or by imaging were studied retrospectively.(Jan 
2010- Dec 2011) The ER/ PR and HER-2neu status of the 
patients was noted and the patients were classified into 
luminal A/B, Triple negative, Her2/neu enriched and 
Luminal/Her. 
All patients had received the treatment for carcinoma breast 
as per the standard protocols i.e. Cuarative treatment with 
surgery, Chemotherapy, and radiotherapy followed by 
hormonal therapy as per the indications. 
All the patients were followed up for local as well as distant 
failure and pattern of failure was co-related with the 
molecular subtypes. 
The major sites of distant metastasis were lungs, liver, bones 
and brain. 
molecular subtypes bone Liver Lungs brain local recurrence 
Luminal A/B 16/30  10/30 2/30 6/30 4/30 
Her 2 Neu enriched 28/66 30/66 20/66 20/56 18/56 
Luminal Her 16/28  11/28 2/28 8/28 6/28 
Triple Negative 7/19 6/19 7/19 4/19 0/19 
       
Results: Brain was the most common site of metastasis in Her 
2 /neu enriched subtype. 
Bone is the most common site of metastasis in all subtypes 
 
Conclusion: A strong association of different metastatic sites 
with the molecular status suggests vigilance about the 
symptoms (metastatic) beforehand. Organ specific metastasis 
may depend on the molecular subtype of the cancer. High 
rate of bone metastasis might be due to the role of bone 
marrow as a homing organ for the cancer cells. Early 
treatment of Her-2/ neu patients withTrastuzumab might 
reduce the rate of metastasis. Tailored strategies against 
distant metastasis concerning the molecular subtypes in 
breast cancer may be considered. 
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Purpose or Objective: Worldwide, breast cancer is the most 
common invasive cancer in women. The management of 
breast cancer depends on multiple factors. The purpose of 
this work is review the currently management of the axilla 
after neoadjuvant systemic therapy in breast cancer 
especially from the point of view of an oncology 
radiotherapist 
 
Material and Methods: In May 2015, we searched clinical trial 
registers, the Cochrane Central Register of Controlled Trials, 
Web of Science, EMBASE and MEDLINE and reviewed 
reference lists. Further hand searches were conducted of 
relevant journal proceedings. At the end, we principally 
reviewed both meta-analyses regarding the results of the SNB 
following NAC in patients with a diagnosis of clinically 
negative axillae, the results of NSABPB-18 and NSABP B-27 
